ABSTRACT
INTRODUCTION
Down syndrome (MIM 190685) , or trisomy 21, is a complex metabolic and genetic disorder that stems from the failure of chromosome 21 to segregate normally during meiosis (1) . More than 80 clinical features have been observed in individuals with trisomy 21, including cognitive impairment, congenital heart disease, and childhood leukemia (2) (3) (4) . These features are complex and involve various combinations of genes and environmental factors. These include allelic heterogeneity for chromosome 21 genes, epistatic interactions (chromosome 21 genes with genes on 21 or on other chromosomes), and environmental events (5) . Many of these clinical features refer to observations in children whose folate requirement may be higher than that of the adults in the present study.
The cystathionine ␤-synthase gene (CBS) on chromosome 21q22.3 codes for a pyridoxal 5'-phosphate-dependent enzyme that condenses homocysteine and serine to form cystathionine (6, 7) . CBS is over-expressed in individuals with trisomy 21 (8) . Another gene on chromosome 21q22.3 (RFC1 or SLC19A1) codes for the reduced folate carrier, which is responsible for 5-methyltetrahydrofolate internalization within cells. Homocysteine is situated at a critical regulatory branch point in the sulfur metabolism produced by cellular demethylation of dietary methionine. It can be remethylated to methionine by the transfer of the methyl group of methyltetrahydrofolate (9) , which requires methionine synthase (5-methyltetrahydrofolate-homocysteine S-methyltransferase) with both vitamin B-12 and S-adenosylmethionine as cofactors, or can be converted to cysteine in the transsulfuration pathway, which requires CBS and vitamin B-6 as cofactors. The release of homocysteine into the extracellular medium represents the third route of cellular homocysteine disposal.
Over the past decade, several contributions have shown that genetic polymorphisms might influence plasma total homocysteine (tHcy) concentrations, either directly or by affecting plasma folate concentrations. Polymorphisms of the 5,10-methylenetetrahydrofolate reductase gene (MTHFR) have been studied extensively in various populations. Suboptimal doses of folate have been shown to increase plasma homocysteine concentrations in the presence of the 677C3 T polymorphism (10) . Many other polymorphisms in genes encoding proteins involved in homocysteine and folate have been reported. A polymorphism in the gene encoding methionine synthase (MTR) results in an adenine-to-guanine substitution at nucleotide 2756 in cDNA (11) , and a polymorphism in the gene encoding methionine synthase reductase (MTRR) results in an adenine-to-guanine substitution at nucleotide 66. Both polymorphisms may be associated with higher tHcy concentrations (12, 13) . For the CBS gene, the most common variation is a 68 -base pair (bp) insertion (844Ins68) polymorphism in the coding region of exon 8 (14) . More recently, we published a polymorphism in the human RFC1 cDNA and hypothesized that it influences plasma tHcy concentrations (15) . This polymorphism is a guanine-to-adenine exchange at nucleotide 80. The RFC1 gene is involved in cellular folate uptake. The effect of the 80G3 A polymorphism has only been studied in a limited way (16) (17) (18) .
The aim of the present study was to evaluate the effect of vitamin supplementation on tHcy concentrations in patients with trisomy 21. We attempted to determine the consequences of orally administered folic acid or folic acid combined with vitamin B-12, vitamin B-6, or both. An additional goal of the study was to analyze the possible influence of the MTHFR 677C3 T, MTHFR 1298A3 C, CBS 844Ins68, MTR 2756A3 G, MTRR 66A3 G, and RFC 80G3 A allele variants on homocysteine concentrations.
SUBJECTS AND METHODS

Subjects
The participants were 160 French individuals (87 men and 73 women) aged 26 Ȁ 4 y (x Ȁ SD; range: 15-46 y) with full trisomy 21 confirmed by karyotype, and 160 healthy, unrelated control subjects matched for sex and age. Controls were enrolled provided that they had no history of cardiovascular disease, cancer, epilepsy, diabetes, or impaired renal function. None of the healthy subjects enrolled used alcohol, anticonvulsants, or antifolate and none took vitamin or mineral supplements. A questionnaire was completed by each participant to indicate whether he or she had taken a vitamin or mineral supplement before the blood sample being given. For persons with trisomy 21, the study included both participants who were taking and those who were not taking vitamin B supplements (folic acid, vitamin B-6, or vitamin B-12). Of the 160 individuals, 25 used no form of vitamin supplements. Other participants used drug-based vitamin B, such as Speciafoldine (contains 5 mg folic acid per pill; Aventis, Paris), MAGNEB 6 (5 mg vitamin B-6 chlorhydrate per vial; Sanofi-Synthelabo, Paris), and vitamin B-12 Aguettant (100 g cyanocobalamin; Aguettant, Lyon, France). Sixty-five persons used folic acid (Speciafoldine) only, 23 persons used folic acid combined with vitamin B-12 (vitamin B-12 Aguettant), 25 persons used folic acid combined with vitamin B-6 (MAGNEB 6 ), and 22 persons used all 3 vitamins. The study protocol was approved by the Ethical Committee for Studies on Humans of the CHU de Nancy, and written informed consent was obtained from the participants' parents or the participants themselves.
Blood sampling and biochemical determination
Fasting blood samples were collected from the participants by venipuncture. After collection, whole blood was kept at 4°C until centrifuged at 400 ҂ g for 15 min. The time elapsing between blood collection and plasma separation was 1 h. Samples were stored at Ҁ80°C until analyzed. The tHcy concentration (the total amount of protein-and non-protein-bound homocysteine) was measured by HPLC with fluorescence detection (19) , involving derivatization with 7-fluorobenzo-2-axo-1,3-diazole-4-sulfonate (SBD-F) according to Ubbink et al (20, 21) . Briefly, after reduction with tri-n-butylphosphine, deproteinization with trichloroacetic acid, centrifugation, and derivatization with SBD-F, the compounds are isocratically separated by C 18 reversed-phase HPLC and quantified by fluorescence detection. The mobile phase was 0.1 mol/L phosphate buffer:acetonitrile (pH 1.5; 94:6 by vol). The excitation and emission wavelengths were 384 and 516 nm, respectively. The retention time was 5 min for Hcy and 11 min for the internal standard (N-acetylcysteine). Red blood cell (RBC) folate, serum folate, and serum vitamin B-12 were measured by immunoassays (Abbott, Rungis, France). The Simul TRAC-SNB Kit (ICN Pharmaceuticals, Orangeburg, NY) uses purified intrinsic factor. In the procedure, endogenous serum binders for both folate and vitamin B-12 are destroyed after incubation with a dithiothreitol tracer for 15 min followed by a 10-min extraction reaction at an alkaline pH. This eliminates the need to heat the sample at 100°C. Vitamin B-12 and folate concentrations are measured simultaneously in a single tube. The vitamin B-12 and folate tracers, binders, and standards are supplied in combined form.
Genomic DNA isolation and analysis by polymerase chain reaction
Human genomic DNA was isolated from peripheral blood samples with NucleoSpin Blood Quick Pure (Machery-Nagel, Cergy Pontoise, France). The MTHFR 677C3 T variant was identified by using polymerase chain reaction (PCR) followed by restriction enzyme digestion of the amplified product (22) (23) (24) . Briefly, PCR primers for amplification of the MTHFR mutation generate a 198-bp fragment. The C3 T substitution at bp 677 creates a HinfI recognition sequence. If the mutation is present, then HinfI digests the 198-bp fragment into 175-and 23-bp fragments that can then be analyzed by electrophoresis.
The common MTR polymorphism that causes an A-to-G transition at bp 2756, converting an aspartic acid (D-919) into glycine, was identified according to the method of Van Der Put et al (25) . Amplified PCR products were digested with the restriction enzyme HaeIII to yield a 265-bp fragment for the wild type 265, 180-and 80-bp fragments for the heterozygote, and 180-and 85-bp fragments for the homozygous recessive genotype.
The MTHFR 1298A3 C polymorphism was measured by using the technique described by Van Der Put et al (26) . An amplified PCR product of 163 bp was digested with the restriction enzyme MboII to yield 56-, 31-, 30-, 28-, and 18-bp fragments for the wild type and 84-, 31-, 30-, and 18-bp fragments for the homozygous recessive genotype.
The MTRR A-to-G transition at bp 66 converting an isoleucine into a methionine residue was identified according to a modified method of Wilson et al (27) and was tested by creating an artificially generated NdeI restriction site. After NdeI digestion, a PCR fragment of 301 bp remains uncut in the presence of the G allele but is cut into 279-and 22-bp fragments in the presence of the A allele.
The common CBS polymorphism that causes an insertion of 68 bp at the 844 position was identified according to the method of Tsai et al (14) . An amplified PCR product of 174 bp was obtained for the wild type, and 242-and 174-bp fragments were obtained for the heterozygote. The 242-bp fragment was digested by BsrI into 200-and 42-bp fragments. The RFC 80G3 A polymorphism was identified as described elsewhere (15) .
Statistical analysis
Statistical analyses were performed by using STATVIEW-5 (SAS Institute Inc, Cary, NC) on a personal computer. Differences in allele frequencies and genotype distribution among the different groups were assessed by chi-square analysis. Results are presented as means Ȁ SEMs. A Mann-Whitney test was used to analyze the effect of vitamin supplementation on blood parameters. A Kruskal-Wallis test was used to measure the effect of age on homocysteine values in different groups. A Bonferroni test was done to check that positive results were not due to the multiplecomparison procedure. Both significant values for the MannWhitney and Bonferroni tests are given in the tables concerned. P values 0.05 were considered statistically significant. A Friedman test was done for each potential interaction: age by treatment, casecontrol by genotype distribution, and genotype by group.
RESULTS
The mean fasting plasma tHcy concentration of the trisomy 21 cases who did not take supplemental vitamins (ie, nonusers: 9.8 Ȁ 0.7 mol/L) was not significantly different from that of the controls (9.4 Ȁ 0.3 mol/L). There were also no significant differences between nonusers and controls in RBC folate, serum folate, or serum vitamin B-12 ( Table 1) . With folate supplementation alone, the mean tHcy concentration in the cases (7.6 Ȁ 0.3 mol/L) was significantly lower than that in the controls (P 0.0003, Mann-Whitney test) and was significantly different from that in nonusers. When folic acid was combined with vitamin B-12, plasma tHcy (7.1 Ȁ 0.6 mol/L) was not significantly different from that in folic acid users. Subjects who took folic acid combined with vitamin B-6 had lower plasma tHcy concentrations (8.0 Ȁ 0.6 mol/L) than did the nonusers, but not significantly so. The plasma tHcy concentration was also significantly lower in cases who took folic acid, vitamin B-12, and vitamin B-6 combined (6.5 Ȁ 0.5 mol/L) than in nonusers (P 0.0001). With folic acid use only, RBC folate and serum folate concentrations were 3.7 and 10.7 times, respectively, the concentrations of nonusers. There was no significant difference in the serum vitamin B-12 concentration with folate use alone.
The subjects were aged 15-46 y. The cases and controls were matched according to age and sex; thus, these variables did not differ between the groups. Forty-seven individuals were aged 20 y, 58 individuals were aged 21-30 y, 49 individuals were aged 31-40 y, and 4 individuals were aged 41-46 y. Because trisomy 21 is associated with a general acceleration in the aging process (28, 29) , we examined plasma tHcy concentrations by age. As shown in Table 2 , the mean tHcy concentration in subjects aged 41-46 y was higher in 3 of the 4 cases with trisomy than in the 4 controls: 13.7 mol/L in the 1 nonuser in this age 1 All values are x Ȁ SEM; n in brackets. There were no significant differences by age (Kruskal-Wallis test) and no significant age-by-treatment interactions (Friedman's test). There was a significant main effect of vitamin usage group: controls versus cases, Mann-Whitney U test P 0.001; nonusers versus vitamin users, Mann-Whitney U test P ҃ 0.0007. group and 16.3 and 9.1 mol/L in 2 users of folic acid and vitamin B-12. Because of the low number of individuals aged 40 y, however, no clear relation between tHcy and age was shown.
To determine the possible influence of genetic factors on biochemical variables, we examined the gene polymorphism distribution of the participants ( Table 3 ). There were no significant differences with respect to MTHFR 677C3 T, MTHFR 1298A3 C, MTR 2756A3 G, or MTRR 2756A3 G genotypes between controls and cases. We also analyzed polymorphisms of CBS and RFC. Both are located on chromosome 21 and should be triploid in individuals with trisomy 21. Because we used an restriction fragment length polymorphism method to analyze the polymorphisms, we were not able to distinguish heteroallelic individuals containing 1 or 2 copies of each allele (for example, an 80AAG genotype could be confused for an 80AGG genotype). However, we were able to clearly differentiate between homoallelic individuals, whether diploid or triploid (80AAA compared with 80GGG). The distribution of the RFC G3 A and CBS 844Ins68 genotypes was consistent with Hardy-Weinberg equilibrium. The distribution of the 80GG and 80AA genotypes in the controls was significantly different from the distribution of the 80GGG and 80AAA genotypes in the cases (P ҃ 0.013). In addition, the distribution of the Ins68Ϫ/Ϫ and Ins68ϩ/ϩ genotypes in the controls was significantly different from the distribution of the Ins68Ϫ/Ϫ Ins68ϩ/ϩϩ genotypes in the cases (P 0.0001). Finally, for both polymorphisms, the wild type homozygous genotype was significantly less frequent among the cases. The lower occurrence of the 844Ins68Ϫ/Ϫ genotype in the cases is consistent with the report of Ge et al (30) .
With respect to MTHFR genotypes and tHcy concentrations in the control group (Table 4) , 677 TT homozygotes had slightly higher tHcy concentrations (statistical significance was borderline with the Mann-Whitney test) associated with lower concentrations of RBC folate (RBC folate data not shown). However, tHcy concentrations in nonusers did not differ significantly according to MTHFR genotype. For users of folic acid ѿ vitamin B-12 ѿ vitamin B-6, the only significant difference marked in Table 4 is between the AA(A) and AG groups. Regarding MTRR genotype and users of folic acid ѿ vitamin B-12 ѿ vitamin B-6, those homozygous for the G allele had significantly higher tHcy concentrations than did those homozygous for the A allele (7.8 Ȁ 0.7 compared with 4.9 Ȁ 0.1 mol/L) and significantly higher RBC folate concentrations. Serum folate and serum vitamin B-12 concentrations were not significantly different.
DISCUSSION
Folic acid supplementation is considered the treatment of choice to prevent functional folate deficiency in trisomy 21. Many parents or guardians of individuals with trisomy 21 are hearing about nutritional supplement formulas that contain B vitamins, which are promoted as correcting metabolic pathways that have gone wrong as the result of the extra chromosome 21. Understanding the factors influencing folic acid responsiveness should assist in the prediction of whether an individual with trisomy 21 would be expected to benefit from these B vitamin 3 Chi-square: difference between controls and cases for mutated allele frequency distribution. 4 The method used in this study does not distinguish individuals who are GGA from those who are GAA, AGA, or AAG. 5 The method used in this study does not distinguish individuals who are Ins68ϪϪϩ from those who are Ins68ϪϩϪ or Ins68Ϫϩϩ.
supplements. It was our objective in the present study to determine how B vitamin use influences plasma tHcy and folate concentrations in patients.
In earlier studies involving other trisomy 21 patients, we (AC) and other investigators showed that the plasma tHcy concentration is lower in trisomy 21 (31, 32) . Lower plasma tHcy concentrations are consistent with a functional folate deficiency resulting from CBS over-expression and higher enzyme activity. The plasma tHcy results in the present trisomy 21 population (the nonusers), however, failed to confirm these main findings between trisomy 21 patients and controls.
Concerning amino acid concentrations in persons with trisomy 21, Lejeune et al (33) showed that the concentrations of serum amino acids in persons with trisomy 21 differ from the concentrations in healthy controls. That study covered a mixed age range and included many adults. However, Heggarty et al (34) failed to find the decrease in aminothiols (cysteine, cystathionine, and methionine) and serine that is supposed to occur in persons with trisomy 21. It is not clear why the fasting plasma tHcy concentration in the nonusers in the present study was not significantly different from that of the controls. One possible explanation for our failure to confirm reduced tHcy concentrations in trisomy 21 may be that we measured tHcy in adults, who have a much lower folate requirement for growth. As shown in Table 4 , the MTHFR 677C3 T polymorphism was not associated with any significant variation in plasma tHcy concentrations among cases or controls. In the absence of a control group of vitamin users, it is difficult to conclude whether the slight increase in tHcy seen in the controls but not in the cases homozygous for the T allele reflected different metabolic backgrounds of the cases and controls. Another issue to study is whether controls would have a similar 10-fold increase in folate concentrations with folic acid vitamin use. If the increase in serum folate in persons with Down syndrome is greater than that in healthy persons, it could indicate a functional folate deficiency (ie, folate is not retained inside the cells).
The genotype results for CBS confirm the earlier report of Ge et al (30) showing a significant high frequency of the CBS Ins68ϩ/Ϫ genotype in trisomy 21. On the other hand, we found a lower frequency of the homozygous RFC1 80AAA genotype in cases than in controls (Table 3 ). In the present study, tHcy concentrations in cases who used folic acid ѿ vitamin B-6 ѿ vitamin (35, 36) . The RFC gene on chromosome 21 is involved in maternal-to-fetal transplacental folate transport. A dosage effect in trisomy 21 and a possible functional effect of the polymorphism may contribute toward an imbalance of one-carbonderived metabolites.
In conclusion, the present study may contribute information concerning the link between the metabolic consequences of additional chromosomal material and polymorphisms in genes related to vitamin metabolism. The study was performed in adults and did not take into account any specific clinical features of down syndrome. Our results suggest that there are no significant differences in fasting blood tHcy concentrations between healthy controls and adult trisomy 21 patients that justify B vitamin supplementation.
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